Selective laser trabeculoplasty (SLT) as replacement therapy in glaucoma patients

Selective laser trabeculoplasty as replacement therapy in glaucoma patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22263

Enrollment

145

Registered

2015-09-23

Start date

2014-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

many local and systemic side effects of anti glaucoma eye drops can be eliminated by using laser and reducing eye drops

Interventions

1,Randomization decides whether patients receive SLT or continue on drops. 2,In those to receive SLT, randomization decides whether indomethacin or dexamethasone drops are given after SLT. 3,SLT is

Eligibility

Inclusion criteria

Inclusion criteria: patients with ocular hypertension or chronic open angle glaucoma controlled by medical therapy. Patients had to be prepared to sign an informed consent document.

Exclusion criteria

Exclusion criteria: other types of glaucoma than open angle glaucoma, previous trabeculectomy or selective laser trabeculoplasty. Corneal disease that inhibit good visualization of the trabecular meshwork and patients taking systemic steroids are excluded

Design outcomes

Primary

Measure	Time frame
1, IOP lowering effect of SLT	—

Secondary

Measure	Time frame
1, inflammatory parameters after SLT ( redness, pain, cells in anterior chamber, IOP spike) 2, quality of life parameters	—

Contacts

Public ContactMyrjam de Keyser

Den Brem 93

myrjam@bijzonder.be00 32 473/89 30 01

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)